Cargando...
Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more?
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group
2006
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1617040/ https://ncbi.nlm.nih.gov/pubmed/16520741 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0706713 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|